Literature DB >> 23127267

Therapeutic hypothermia for febrile infection-related epilepsy syndrome in two patients.

Jainn-Jim Lin1, Kuang-Lin Lin, Shao-Hsuan Hsia, Huei-Shyong Wang.   

Abstract

Despite advances in critical care, febrile infection-related epilepsy syndrome remains the most important cause of mortality and neurologic deficits during childhood. Only a few therapeutic agents were reported to shorten the acute phase and improve outcomes. Therapeutic hypothermia was reported effective in stabilizing immune activation, brain edema, and seizure activity, to protect the brain from ongoing functional, apoptotic neural, and glial damage and the systemic expansion of the cytokine storm. We present two pediatric cases of febrile infection-related epilepsy syndrome, refractory to conventional medical therapy. Moderate therapeutic hypothermia at 33°C resulted in fast, sustained control of refractory status epilepticus. After 3 months, both patients recovered with a Glasgow Outcome Scale score of 4. Therapeutic hypothermia may play an important role in children with febrile infection-related epilepsy syndrome.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23127267     DOI: 10.1016/j.pediatrneurol.2012.08.013

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  11 in total

1.  Management of pediatric status epilepticus.

Authors:  Nicholas S Abend; Tobias Loddenkemper
Journal:  Curr Treat Options Neurol       Date:  2014-07       Impact factor: 3.598

2.  Hypothermia for pediatric refractory status epilepticus.

Authors:  Kristin Guilliams; Max Rosen; Sandra Buttram; John Zempel; Jose Pineda; Barbara Miller; Michael Shoykhet
Journal:  Epilepsia       Date:  2013-08-01       Impact factor: 5.864

Review 3.  Status epilepticus and refractory status epilepticus management.

Authors:  Nicholas S Abend; David Bearden; Ingo Helbig; Jennifer McGuire; Sona Narula; Jessica A Panzer; Alexis Topjian; Dennis J Dlugos
Journal:  Semin Pediatr Neurol       Date:  2014-12-12       Impact factor: 3.042

Review 4.  Management of Status Epilepticus in Children.

Authors:  Douglas M Smith; Emily L McGinnis; Diana J Walleigh; Nicholas S Abend
Journal:  J Clin Med       Date:  2016-04-13       Impact factor: 4.241

5.  Marked improvement in febrile infection-related epilepsy syndrome after lidocaine plus MgSO4 treatment in a 12-year-old girl.

Authors:  I-Ching Chou; Huan-Cheng Lai; Fuu-Jen Tsai; Yu-Tzu Chang; Sheng-Shing Lin; Syuan-Yu Hong; Inn-Chi Lee
Journal:  Epilepsy Behav Case Rep       Date:  2016-06-02

Review 6.  Targeted temperature management in the ICU: guidelines from a French expert panel.

Authors:  Alain Cariou; Jean-François Payen; Karim Asehnoune; Gerard Audibert; Astrid Botte; Olivier Brissaud; Guillaume Debaty; Sandrine Deltour; Nicolas Deye; Nicolas Engrand; Gilles Francony; Stéphane Legriel; Bruno Levy; Philippe Meyer; Jean-Christophe Orban; Sylvain Renolleau; Bernard Vigue; Laure De Saint Blanquat; Cyrille Mathien; Lionel Velly
Journal:  Ann Intensive Care       Date:  2017-06-19       Impact factor: 6.925

Review 7.  Application of ketogenic diets for pediatric neurocritical care.

Authors:  Kuang-Lin Lin; Jann-Jim Lin; Huei-Shyong Wang
Journal:  Biomed J       Date:  2020-07-05       Impact factor: 4.910

Review 8.  Clinical application of target temperature management in children with acute encephalopathy-A practical review.

Authors:  Jainn-Jim Lin; Shao-Hsuan Hsia; Ming-Chou Chiang; Kuang-Lin Lin
Journal:  Biomed J       Date:  2020-06-28       Impact factor: 4.910

9.  Therapeutic hypothermia for pediatric refractory status epilepticus May Ameliorate post-status epilepticus epilepsy.

Authors:  Mei-Hsin Hsu; Hsuan-Chang Kuo; Jainn-Jim Lin; Ming-Yi Chou; Ying-Jui Lin; Pi-Lien Hung
Journal:  Biomed J       Date:  2020-04-21       Impact factor: 4.910

Review 10.  Neurocritical care and target immunotherapy for febrile infection-related epilepsy syndrome.

Authors:  Hiroshi Sakuma; Asako Horino; Ichiro Kuki
Journal:  Biomed J       Date:  2020-04-21       Impact factor: 4.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.